frontMIND - A new treatment for newly diagnosed lymphoma

Lymphoma

The frontMIND trial is testing a new treatment for patients who have been recently diagnosed with a type of blood cancer called Diffuse Large B-Cell Lymphoma (DLBCL). The study investigates the safety and effectiveness of investigational drug tafasitamab plus lenalidamide. The study aims to determine if addition of the investigational drug to standard therapy for DLBCL improves treatment outcomes for patients compared to standard therapy on its own.

Category
Trial Status
Active, not recruiting
Trial Phase
Phase 3 Drug Trial
Trial contact details
Contact Person
Kim Green - Clinical Research Coordinator
What you need to know

Who can take part?

  • People who have been recently diagnosed and not begun treatment for DLBCL, grade 3b Follicular Lymphoma and certain rare forms of B-cell lymphoma
  • People with no prior history of blood cancers or other cancers, aside from some skin cancers
  • People of reproductive potential must avoid pregnancy during the study

What is involved for you?

Participants will be randomly assigned to receive investigational drug plus standard chemotherapy, by intravenous infusion, or standard chemotherapy alone.  They also undergo the following tests:

  • Physical exams
  • Heart rate & blood pressure
  • Electrocardiogram
  • Blood tests
  • Urine tests
  • Imaging scans:  PET/CT
  • CT or MRI scan
  • Echocardiogram
  • Bone marrow biopsy
  • A tumour biopsy may be required, if samples from a diagnostic biopsy are not available
  • Questionnaires

All research clinical trials news

2023 was an outstanding year for Mater Research with $13.7 million in grant funding received and 424 publications recorded.

29

Feb

Highlighting Mater Research’s year of achievements: 2023 Annual Report

When Monique Perry was diagnosed with aggressive triple-negative breast cancer she feared her family history was about to repeat itself.

27

Oct

Clinical trials give Queensland breast cancer patients hope

Mater researchers in Brisbane are leading a trial of a game-changing flu vaccine that has the potential to provide greater and more durable protection against the virus.

23

May

Mater launches trial of Australian-first flu vaccine

Displaying results 1-3 (of 18)
 |<  < 1 - 2 - 3 - 4 - 5 - 6  >  >|